MedTrace Logo

Bivalirudin in Stable Ischemic Heart Disease Patients Undergoing PCI

NCT02787317 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1770

Last updated 2016-06-01

No results posted yet for this study

Summary

Prolonging infusions may decrease myocardial damage associated with bivalirudin use during primary PCI. The investigators hypothesized that continuing the bivalirudin infusion commenced during the procedure at the PCI recommended dose for 4 hours would prevent myocardial damage.

Conditions

  • Coronary Disease

Interventions

DRUG

bivalirudin

Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention.

DRUG

Heparin

Heparin is used in patients undergoing percutaneous coronary intervention.

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2017-10-31
Completion
2018-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02787317 on ClinicalTrials.gov